

# Health Effects of Small Volatile Compounds from East Asian Medicinal Mushrooms

Kayla K. Pennerman\*, Guohua Yin and Joan Wennstrom Bennett

*Department of Plant Biology and Pathology, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA*

**Abstract** Medicinal fungi, taken whole or as various forms of extracts, have been used to alleviate, cure or prevent human ailments since pre-historic times. In particular, Asian cultures have incorporated a variety of mushrooms into their medical practices. Chemically pure, bioactive metabolites from fungi have been a mainstay of modern pharmacological research and in addition to antibiotics, include anticancer agents, immunosuppressants, enzyme inhibitors, antagonist and agonists of hormones, and a variety of psychotropic substances. However, to date not many studies have focused on the possible health benefits of odorant volatile organic compounds (i.e., gas phase compounds). An analysis of these compounds for their health related effects will expand the range of compounds available for the treatment of chronic and acute diseases. This review highlights phenolic acids and monoterpenes from Asian medicinal mushrooms (AMMs), which not only produce pleasant odors but also have antioxidant and antibacterial effects. Odorant bioactive volatile phase compounds from medicinal mushrooms remain an essentially untapped source for future medicines, and AMMs remain a promising resource for future pharmacological research.

**Keywords** Antimicrobial, Antioxidant, Monoterpene, Odor, Phenolic acid

Scientists who study traditional healing practices are in pursuit of a unified concept of medicine in which the use of complex mixtures of natural compounds from mushrooms and plants can be integrated with contemporary Western approaches that use purified single crystalline compounds as drugs. In particular, natural products with antimicrobial properties (antibiotics) transformed therapeutic medicine and changed the character of the modern pharmaceutical industry. While useful drugs have been developed from many different bacterial, fungal and plant sources, it is interesting to note that of the approximately 200,000 known natural products, approximately one quarter are fungal metabolites [1].

Most pharmaceutical research has focused on the discovery of new antibiotics and other therapeutics such

as antihypertensives, anticancer agents, antiparasitics and immunosuppressants. Botanists, microbiologists and mycologists categorize such compounds together as “secondary metabolites”, i.e., members of a chemically heterogeneous group of low molecular weight natural products that are produced by specialized biosynthetic pathways and that serve apparently “dispensable” functions [2-4]. Specific secondary metabolites are usually restricted to narrow taxonomic groups where they are biosynthesized by gene clusters [5]. Bioinformatics features of putative alkaloid, non-ribosomal polypeptide, polyketide and terpenoid pathways can be detected by their distinctive genomic signatures in fungal genome data, and many cryptic pathways have been discovered in recent years [5]. It is now believed that many organisms encode the potential to produce many more secondary metabolites than originally expected [6].

In this review, we focus on a group of even lower weight natural products that are easily volatilized. These gas phase metabolites are responsible for the distinctive aroma properties of different organisms and have received relatively little attention by pharmacologists in their search for new bioactive metabolites. In particular, our review will target phenolic and monoterpene compounds from Asian medicinal mushrooms (AMMs).

## VOLATILE ORGANIC COMPOUNDS

Volatile organic compounds (VOCs) are low molecular mass, carbon-containing compounds that readily evaporate

Mycobiology 2015 March, 43(1): 9-13  
<http://dx.doi.org/10.5941/MYCO.2015.43.1.9>  
pISSN 1229-8093 • eISSN 2092-9323  
© The Korean Society of Mycology

**\*Corresponding author**

E-mail: [k.pennerm@rutgers.edu](mailto:k.pennerm@rutgers.edu)

**Received** January 6, 2015

**Revised** March 3, 2015

**Accepted** March 3, 2015

©This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

at normal atmospheric temperatures and pressures [7]. Fungi produce VOCs of many molecular sizes and include acids, alcohols, aldehydes, aromatics, esters, heterocyclics, ketones, phenols, terpenes, thiols and so forth. Over 300 different VOCs have been identified from fungi where they are usually produced as complex mixtures in individually low concentrations [8]. The shortage of investigations into the health effects of these compounds in fungi is related in part to the difficulties in sample preparation, extraction and concentration of odorant molecules that are often found in the parts-per-billion range. It can be difficult to isolate sufficient amounts of them for physiological studies and characterization [9]. Furthermore, some VOCs have negative health effects. Perhaps the best-studied volatiles are industrial compounds such as chemical solvents (benzene, carbon tetrachloride, chloroform, formaldehyde, glycol ethers, methylene chloride, toluene, and so forth), many of them have widespread commercial application and are known to have both short and long-term negative effects on human health [10]. Far less is known about the possible health effects of biogenic VOCs, either beneficial or deleterious.

The many functionalities of fungal VOCs and their roles in interorganismal interactions have been reviewed by Bitas *et al.* [11]. The single most abundant volatile produced by mushrooms is 1-octen-3-ol, also known as “mushroom alcohol,” which gives many commercially available edible mushrooms their characteristic smell and which has an extremely low (0.01 ppm) odor threshold in humans [1]. Mushroom alcohol has been isolated from almost every fungal species studied. It is widely used as a food and flavoring agent as well as a component of perfumes. Moreover, the compound is suspected to contribute to “sick building syndrome,” causing headaches, dizziness and nausea in those exposed to it [12]. Our lab also has demonstrated that mushroom alcohol induces neurotoxic effects in a *Drosophila melanogaster* model for Parkinson’s disease [13, 14] and found that it is 80 times more toxic than toluene in human embryonic stem cells [15].

## MEDICINAL MUSHROOMS

For centuries, cultures across the globe have used mushrooms for nourishment, medication and creative inspiration. As natural remedies, mushrooms and mushrooms extracts are utilized in the treatment and prevention of acute and chronic ailments including asthma, cancer, heart disease, infections, insomnia and ulcers. The medical traditions of China, Japan and Korea, in particular, have incorporated some of the most ancient, distinctive and widely used fungal remedies. The major fungi used in traditional East Asian medical practices include *Ophiocordyceps sinensis* (Chinese: dōng chóng xià cǎo; English: caterpillar mushroom), *Ganoderma lucidum* (Chinese: líng zhī; Japanese: reishi), *Grifola frondosa* (Chinese: huī shù huā; Japanese: maitake; English: chicken-of-the-woods), *Hericiium erinaceus* (Chinese: hóu tóu; Korean: norugongdengi beoseot; English: lion’s

mane mushroom), *Antrodia camphorata* (Chinese: niu chang), *Flammulina velutipes* (Chinese: jīn zhēn gū; Korean: paengi beoseot; Japanese: enokidake) and *Lentinula edodes* (Chinese: xiāng gū; Japanese: shiitake). Traditionally, these mushrooms are ingested whole or extracts containing the curative compounds are prepared by boiling the fruiting bodies in water; many modern commercial products are also available consisting of powdered or pill forms of the mycelia, fruiting bodies and/or spores [16].

Numerous studies have been published on the therapeutic compounds found within medicinal fungi. Scientific research on beneficial fungal compounds primarily focus on macromolecules (polysaccharides, proteins and lipids) or non-volatile secondary metabolites with molecular masses of approximately 300–900 g/mol. For example, the antitumor properties of *Pleurotus* spp. have been attributed to (1 → 3)-β-D-glucans while complex branched polysaccharides, and triterpenes are considered the major pharmacological components of *G. lucidum* [16]. However, medicinal mushrooms also produce a considerable quantity of smaller less-studied, fragrant compounds with putative health benefits and detriments.








## AMM PHENOLICS ACIDS AND MONOTERPENES

For the sake of this review, we emphasize two groups of active compounds which have been isolated from AMMs: simple phenolic acids and monoterpenes (Table 1) [17–27]. Phenolic acids are a class of organic compounds containing an aromatic benzene ring directly bonded to a hydroxyl group and a carboxylic acid substituent. Generally known and marketed for their antioxidant prowess and other health promotion activities in plant foods such as berries and teas, studies have turned to determining the absorption and circulation of phenolic compounds within consumers, as recently reviewed by Velderrain-Rodríguez *et al.* [28]. Terpenes, which are secondary metabolites biosynthetically derived from isoprenes, are the largest known group of natural products and have been largely characterized from plants. As many of them have pleasant odors, they have been intensively researched by the food and flavor industries [29]. Less is known about their health effects.

Similarly, not much is known about the biosynthesis of either of these groups of compounds in fungi. In plants, phenols are produced mostly through shikimate and acetate pathways [28]. Bacteria and fungi are known to biotransform or biodegrade camphor, *p*-cymene and citronellol/geraniol [30]. Using bioinformatics predictions, more pathways and the involved enzymes can be annotated [5, 30]. It is also possible that some of these compounds may be obtained from the surrounding environment as in the case of α-terpineol, which seems to act as an extracellular signal for the production of triterpenes in *A. camphorata* [26].

Total phenol content within *G. lucidum*, *F. velutipes*, *Panus tigrinus* and other AMM extracts range from 0.2 to

**Table 1.** Six odorous phenolic acid and monoterpene compounds found in Asian medicinal mushrooms


IUPAC name and <u>synonym</u>	Structure	Odor	Associated AMM
<b>Phenolic acids</b>			
(E)-3-Phenylprop-2-enoic acid <u>Cinnamic acid</u>		Honey-like	<i>Ganoderma lucidum</i> [17] <i>Lentinula edodes</i> [18] <i>Pleurotus eryngii</i> [18] <i>Pleurotus ostreatus</i> [18]
3,4-Dihydroxybenzoic acid <u>Protocatechuic acid</u>		Phenolic	<i>Agaricus blazei</i> [19] <i>Flammulina velutipes</i> [19, 20] <i>G. lucidum</i> [19, 21] <i>Inonotus obliquus</i> [19] <i>L. edodes</i> [19] <i>Ophiocordyceps sinensis</i> [21] <i>Phellinus linteus</i> [19] <i>P. eryngii</i> [19] <i>P. ostreatus</i> [19, 20] <i>Trametes versicolor</i> [20] <i>Sparassis crispa</i> [19]
4-Hydroxy-3-methoxybenzoic acid <u>Vanillic acid</u>		Vanilla-like	<i>S. crispa</i> [19]
<b>Monoterpenes</b>			
3,7-dimethylocta-1,6-dien-3-ol <u>Linalool</u>		Floral	<i>G. lucidum</i> [22] <i>Hericium erinaceus</i> [23] <i>Piptoporus betulinus</i> [24]
1-Methyl-4-(1-methylethenyl)-cyclohexene <u>Limonene</u>		Citrusy	<i>G. lucidum</i> [22] <i>H. erinaceus</i> [23] <i>Lentinula edodes</i> [25]
2-(4-Methyl-1-cyclohex-3-enyl)propan-2-ol <u>α-Terpineol</u>		Fruity-spicy	<i>Antrodia camphorata</i> [26] <i>G. lucidum</i> [22] <i>P. betulinus</i> [24] <i>P. eryngii</i> [27]
1-Methyl-4-(prop-1-en-2-yl)-cyclohexan-1-ol <u>β-Terpineol</u>		Woody	<i>A. camphorata</i> [26] <i>H. erinaceus</i> [23]

Note: Chemical structures were generated using ChemDoodle 2D sketcher (<http://web.chemdoodle.com/demos/sketcher>).

10 mg/g (in terms of chlorogenic acid equivalents; measured using Folin-Ciocalteu reagent), while individual concentrations of some phenolic acid compounds are up to 3 mg/g [20]. Protocatechuic acid is one of the highest accumulating simple phenolic acids in some AMMs [18-20]. Mushroom extracts also have been found to have 25~50% terpene content by gas chromatography-mass spectrometry with some monoterpenes present at up to nearly a fifth of the extract [26, 27]. However, the phenolic acid and monoterpene compounds presented in Table 1 accumulate at lower concentrations. For example, when detected, limonene is only 0.1% to 0.9% of an extract [23, 24, 27]. The highest-accumulating monoterpene found to date in an AMM is eucalyptol in *A. camphorata* at 18% [26].

As with other VOCs, the concentrations of phenolic

acids and monoterpenes vary among parts of the mushrooms and with growth conditions. In *G. lucidum*, the fruiting body has a higher phenol content (12.3 µg/g dry mushroom mass) than does the mycelia harvested from liquid cultures (2.5 µg/g dry hyphal mass) [17]. In *A. camphorata*, only the fruiting bodies contain α-terpineol [26]. Conversely, in *Pleurotus ostreatus*, cinnamic acid is present at a much higher concentration in the mycelia from liquid cultures than in whole mushroom fruiting bodies [18]. Moreover, the concentrations and identities of these compounds may fluctuate due to differences in the origin of the fungus and the substrate on which it grows. Karaman *et al.* [20] found much higher concentrations of phenolic acids in wild Serbian mushrooms than Reis *et al.* [18] did in mushrooms bought at Portuguese supermarkets. Within the same study,



**Fig. 1.** Relevant publications in PubMed. As of this writing, an NCBI PubMed search of “medicinal mushroom” yields 860 relevant publications of which 851 are research journal articles. While there is a definite increase in publications, it is miniscule compared to the nearly exponential surge seen in other fields.

Rösecke *et al.* [24] detected noticeably different terpene concentrations in *Piptoporus betulinus* from the same source. Finally, the kinds of detected VOCs are also a reflection of the extraction and analytical procedures that are applied [31]. While Karaman *et al.* [20] and Reis *et al.* [18] used different dilutions of methanol, chloroform and ethanol to extract phenolic compounds from powdered fruiting bodies, Kim *et al.* [19] utilized a mixture of acetonitrile and hydrochloric acid. Even methods to generate and store powdered mushrooms differ among these studies. Karaman *et al.* [20] air-dried mushrooms at 50°C before pulverization and storing the powder at room temperature in the dark. Kim *et al.* [19] freeze-dried the mushroom powder before use.

Both phenolic acids and monoterpenes have antioxidant and antimicrobial properties. In fact, most of the antioxidant compounds in commercial AMMs are phenols, especially phenolic acids [20]. The phenol content in mushroom extracts positively correlates with antioxidant and antibacterial activity [20]. Crude AAM extracts generally exhibit effective concentration and inhibitory concentration ( $IC_{50}$ ) ratios for antioxidant activity at 0.15–0.85 mg/mL [20]. The monoterpenes  $\alpha$ -terpineol and linalool have comparable  $IC_{50}$ 's around 0.3% (v/v) [32]. Cinnamic acid and one of its metabolites have minimum  $IC_{50}$ 's of 0.7–30  $\mu$ g/mL against certain bacteria and fungi [33], while those of  $\alpha$ -terpineol and linalool against several bacteria range from 0.5% to 2% [32]. For cinnamic acid and its metabolic derivative, the  $IC_{50}$ 's were generally lower than those of commercial antibiotics streptomycin, ampicillin, bifonazole and ketoconazole. Combinations of monoterpenes may lead to additive or synergistic antibacterial effects [32].

## PERSPECTIVES

Purified fungal secondary metabolites such as the  $\beta$ -lactams and statins helped revolutionize twentieth century medicine and have become significant part of humanity's success in

treating disease. Consequently, the economic value of products derived from these natural sources is in the billions of dollars [29, 34]. Similarly, even in the absence of rigorous scientific evidence of their efficacies, used both as remedies and as functional foods, medicinal mushrooms are globally popular and lucrative products. For example, the market value of *G. lucidum* products was estimated at US \$1,628 million in 1995; global mushroom production was in terms of thousands of metric tons the following year [16]. In Western countries alone, the annual market value of *G. lucidum* products was estimated at over US \$1.5 billion in 2006 [16]. It is likely that the market value of traditional fungal medicines have since increased. Unfortunately, rigorous scientific research on the effectiveness of AMMs has not kept pace with the interest; the number of publications relating to AMMs is still small compared to the huge overall volume of pharmacological research (Fig. 1).

While *in vitro* studies using cell cultures have yielded promising results, scientific evidence of *in vivo* effects is still largely limited to anecdotal consumer feedback. Along with the practical difficulties in isolating and identifying VOC compounds, this dearth of overall clinical research into AMMs limits our knowledge of the possible health benefits and economic values of small fungal odorous compounds. Given the ever-increasing preference for natural products and alternative medicine, it is hoped that well-controlled clinical trials will be conducted in the future to determine the benefits of small volatiles after ingestion, inhalation or dermal application. In summary, despite some progress, the scientific study of the health effects of small molecules made by medicinal fungi, especially volatile odiferous compounds, is still in its infancy. We hope this review will stimulate increased interest in their study and change the paradigms of both toxicology and drug discovery research so that they pay more attention to the underexplored medicinal impact of gas phase molecules from fungi.

## REFERENCES

1. Hanson JR. The chemistry of fungi. Cambridge: Royal Society of Chemistry; 2008.
2. Bennett JW. From molecular genetics and secondary metabolism to molecular metabolites and secondary genetics. *Can J Bot* 1995;73:917-24.
3. Bennett JW, Bentley R. What's in a name? Microbial secondary metabolism. *Adv Appl Microbiol* 1989;34:1-28.
4. Bentley R, Bennett JW. Biosynthesis of secondary metabolites. In: Berry DR, editor. *Physiology of industrial fungi*. Oxford: Blackwell Scientific Publications; 1988. p. 161-83.
5. Keller NP, Turner G, Bennett JW. Fungal secondary metabolism: from biochemistry to genomics. *Nat Rev Microbiol* 2005;3: 937-47.
6. Breitling R, Cenicerros A, Jankevics A, Takano E. Metabolomics for secondary metabolite research. *Metabolites* 2013;3:1076-83.
7. Herrmann A. The chemistry and biology of volatiles. Chichester:

- John Wiley & Sons Ltd.; 2010.
8. Korpi A, Järnberg J, Pasanen AL. Microbial volatile organic compounds. *Crit Rev Toxicol* 2009;39:139-93.
  9. Morath SU, Hung R, Bennett JW. Fungal volatile organic compounds: a review with emphasis on their biotechnological potential. *Fungal Biol Rev* 2012;26:73-83.
  10. McFee DR, Zavon P. Solvents. In: Plog BA, editor. *Fundamentals of industrial hygiene* 5th ed. Chicago: National Safety Council; 1988. p. 95-121.
  11. Bitas V, Kim HS, Bennett JW, Kang S. Sniffing on microbes: diverse roles of microbial volatile organic compounds in plant health. *Mol Plant Microbe Interact* 2013;26:835-43.
  12. Wälinder R, Ernstgård L, Norbäck D, Wieslander G, Johanson G. Acute effects of 1-octen-3-ol, a microbial volatile organic compound (MVOC): an experimental study. *Toxicol Lett* 2008;181:141-7.
  13. Inamdar AA, Hossain MM, Bernstein AI, Miller GW, Richardson JR, Bennett JW. Fungal-derived semiochemical 1-octen-3-ol disrupts dopamine packaging and causes neurodegeneration. *Proc Natl Acad Sci U S A* 2013;110:19561-6.
  14. Inamdar AA, Masurekar P, Hossain M, Richardson JR, Bennett JW. Signaling pathways involved in 1-octen-3-ol-mediated neurotoxicity in *Drosophila melanogaster*: implication in Parkinson's disease. *Neurotox Res* 2014;25:183-91.
  15. Inamdar AA, Moore JC, Cohen RI, Bennett JW. A model to evaluate the cytotoxicity of the fungal volatile organic compound 1-octen-3-ol in human embryonic stem cells. *Mycopathologia* 2012;173:13-20.
  16. Chang ST, Miles PG. *Mushrooms: cultivation, nutritional value, medicinal effect, and environmental impact*. 2nd ed. Boca Raton: CRC Press; 2004.
  17. Heleno SA, Barros L, Martins A, Queiroz MJ, Santos-Buelga C, Ferreira IC. Fruiting body, spores and *in vitro* produced mycelium of *Ganoderma lucidum* from northeast Portugal: a comparative study of the antioxidant potential of phenolic and polysaccharidic extracts. *Food Res Int* 2012;46:135-40.
  18. Reis FS, Martins A, Barros L, Ferreira IC. Antioxidant properties and phenolic profile of the most widely appreciated cultivated mushrooms: a comparative study between *in vivo* and *in vitro* samples. *Food Chem Toxicol* 2012;50:1201-7.
  19. Kim MY, Seguin P, Ahn JK, Kim JJ, Chun SC, Kim EH, Seo SH, Kang EY, Kim SL, Park YJ, et al. Phenolic compound concentration and antioxidant activities of edible and medicinal mushrooms from Korea. *J Agric Food Chem* 2008;56:7265-70.
  20. Karaman M, Jovin E, Malbaša R, Matavuly M, Popović M. Medicinal and edible lignicolous fungi as natural sources of antioxidative and antibacterial agents. *Phytother Res* 2010;24:1473-81.
  21. Stilinović N, Škrbić B, Živančev J, Mrmoš N, Pavlović N, Vukmirović S. The level of elements and antioxidant activity of commercial dietary supplement formulations based on edible mushrooms. *Food Funct* 2014;5:3170-8.
  22. Campos Ziegenbein F, Hanssen HP, König WA. Secondary metabolites from *Ganoderma lucidum* and *Spongiporus leucomallellus*. *Phytochemistry* 2006;67:202-11.
  23. Miyazawa M, Matsuda N, Tamura N, Ishikawa R. Characteristic flavor of volatile oil from dried fruiting bodies of *Hericium erinaceus* (Bull.: Fr.) Pers. *J Essent Oil Res* 2008;20:420-3.
  24. Rösecke J, Pietsch M, König WA. Volatile constituents of wood-rotting Basidiomycetes. *Phytochemistry* 2000;54:747-50.
  25. Çağlarirmak N. The nutrients of exotic mushrooms (*Lentinula edodes* and *Pleurotus* species) and an estimated approach to the volatile compounds. *Food Chem* 2007;105:1188-94.
  26. Lu ZM, Geng Y, Li HX, Sun Q, Shi JS, Xu ZH. Alpha-terpineol promotes triterpenoid production of *Antrodia cinnamomea* in submerged culture. *FEMS Microbiol Lett* 2014;358:36-43.
  27. Usami A, Motooka R, Nakahashi H, Okuno Y, Miyazawa M. Characteristic odorants from bailingu oyster mushroom (*Pleurotus eryngii* var. *tuoliensis*) and summer oyster mushroom (*Pleurotus cystidiosus*). *J Oleo Sci* 2014;63:731-9.
  28. Velderrain-Rodríguez GR, Palafox-Carlos H, Wall-Medrano A, Ayala-Zavala JF, Chen CY, Robles-Sánchez M, Astiazaran-García H, Alvarez-Parrilla E, González-Aguilar GA. Phenolic compounds: their journey after intake. *Food Funct* 2014;5:189-97.
  29. Tkacz JS, Lange L. *Advances in fungal biotechnology for industry, agriculture, and medicine*. New York: Kluwer Academic/Plenum Publishers; 2004.
  30. Marmulla R, Harder J. Microbial monoterpene transformations: a review. *Front Microbiol* 2014;5:346.
  31. Zhang Z, Li G. A review of advances and new developments in the analysis of biological volatile organic compounds. *Microchem J* 2010;95:127-39.
  32. Zengin H, Baysal AH. Antibacterial and antioxidant activity of essential oil terpenes against pathogenic and spoilage-forming bacteria and cell structure-activity relationships evaluated by SEM microscopy. *Molecules* 2014;19:17773-98.
  33. Heleno SA, Ferreira IC, Esteves AP, Ćirić A, Glamočlija J, Martins A, Soković M, Queiroz MJ. Antimicrobial and demelanizing activity of *Ganoderma lucidum* extract, *p*-hydroxybenzoic and cinnamic acids and their synthetic acetylated glucuronide methyl esters. *Food Chem Toxicol* 2013;58:95-100.
  34. An Z. *Handbook of industrial mycology*. New York: Marcel Dekker; 2005.